HomeSHTDF • OTCMKTS
add
Sinopharm Group Co Ltd
Previous close
$1.97
Year range
$1.97 - $2.95
Market cap
62.88B HKD
P/E ratio
-
Dividend yield
-
Primary exchange
HKG
In the news
Financials
Income Statement
Revenue
Net income
(CNY) | Jun 2024info | Y/Y change |
---|---|---|
Revenue | 147.46B | -5.13% |
Operating expense | 6.38B | -2.07% |
Net income | 2.28B | -9.16% |
Net profit margin | 1.55 | -4.32% |
Earnings per share | — | — |
EBITDA | 5.57B | -12.42% |
Effective tax rate | 21.74% | — |
Balance Sheet
Total assets
Total liabilities
(CNY) | Jun 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 43.33B | 26.05% |
Total assets | 429.58B | 2.85% |
Total liabilities | 307.15B | 0.84% |
Total equity | 122.43B | — |
Shares outstanding | 3.12B | — |
Price to book | 0.08 | — |
Return on assets | 2.96% | — |
Return on capital | 5.84% | — |
Cash Flow
Net change in cash
(CNY) | Jun 2024info | Y/Y change |
---|---|---|
Net income | 2.28B | -9.16% |
Cash from operations | 6.49B | 346.39% |
Cash from investing | -1.29B | -269.35% |
Cash from financing | -602.70M | -425.16% |
Net change in cash | 4.59B | 374.61% |
Free cash flow | -22.56B | 29.73% |
About
Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical.
Its H shares were listed on the Hong Kong Stock Exchange in 2009, with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted.
Sinopharm Group was ranked 829th in 2016 Forbes Global 2000 list. Wikipedia
Founded
2003
Website
Employees
113,635